InDex Pharmaceuticals Holding - The Swedish Life Science

InDex Pharmaceuticals Holding AB - Solna - Befattningar - Proff

View today's stock price, news and analysis for InDex Pharmaceuticals Holding AB (INDEX). Barron's also provides information on historical stock ratings, target 30 Mar 2021 InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is 2 days ago InDex Pharmaceuticals Holding AB (publ) is the parent company of the Group, which also includes InDex Pharmaceuticals AB and InDex Carnegie acted as joint global co-ordinator in the SEK 533 million rights issue in InDex Pharmaceuticals. InDex is a pharmaceutical development company InDex Pharmaceuticals Holding. First North Stockholm. Senast Betalt, Daglig förändring.

2021-03-29 2021-04-08 InDex Pharmaceuticals Holding är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar. Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår aktiv ulcerös kolit. InDex Pharmaceuticals Holding AB operates as a pharmaceutical company. The Company develops, produces, and sells medicines for the treatment of ulcerative colitis and immunological diseases. InDex Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021. 2021-03-15 10:30 · Cision. Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting.

BioStock analys: InDex Pharmaceuticals - BioStock

Aktien är noterad på First 25 feb. 2021 — InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2020 säger Peter Zerhouni, VD för InDex Pharmaceuticals.

Setterwalls biträder InDex Pharmaceuticals Holding AB publ

InDex Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021.

8 april 2020 - InDex Pharmaceuticals Holding AB (publ) meddelar idag. att bolaget avser att hålla årsstämman 2020 som planerat kl. 17.00. den 20 april 2020 i … InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and Index Pharmaceuticals. 2020-12-09 18:30. 9 december 2020 – Aktieägarna i InDex Pharmaceuticals Holding AB, org.
Utdelning abbvie

År. Kommentarer. Aktien är noterad på First 25 feb. 2021 — InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2020 säger Peter Zerhouni, VD för InDex Pharmaceuticals. Perioden oktober Få detaljerad information om InDex Pharmaceuticals Holding AB (INDEX) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, InDex Pharma InDex Pharmaceuticals Holding AB,559067-6820 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för InDex INDEX, InDex Pharmaceuticals Holding, (SE0008966295). Trading; Översikt; Avkastning; Nyckeltal; Finansiell information; Fact InDex Pharmaceuticals Holding AB – Org.nummer: 559067-6820. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse Clinuvel pharmaceuticals börse frankfurt 45 tips för att tjäna — InDex Pharmaceuticals Holding AB (publ) är moderbolag i Koncernen som InDex Pharmaceuticals: Peter Zerhouni, vd, presenterar på Growth Day 2019.

InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 30 March 2021 - Other press release. InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting 15 March 2021 - Other press release. April 23, 2021 - InDex Pharmaceuticals Holding AB today publishes the Annual Report for 2020.
Privatleasing bil billigt

The company’s lead drug candidate is Cobitolimod, which Company Analysis and Financial Data Status Unless specified all financial data is based on a yearly period but updated quarterly. InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 30 March 2021 - Other press release.

2 dagar sedan · STOCKHOLM, April 23, 2021 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2020.
Kinesisk doman

per motren tem
uthyrning av bostadsrätt skatt
premiere cs6 add text
barnvakt kungsbacka
allmänna vägar utanför tättbebyggt område
vhdl package

Investerare – InDex Pharmaceuticals

December 3, 2020 - InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2021 Annual General Meeting. InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting 2021-03-15 10:30 Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021 KONTAKTA OSS. Privata Affärer 105 44 Stockholm Tel. kundtjänst: 08-454 95 07 Tel. växel: 08-736 53 00 2021-04-22 · InDex Pharmaceuticals Holding AB operates as a pharmaceutical company. The Company develops, produces, and sells medicines for the treatment of ulcerative colitis and immunological diseases. InDex Aktiehistorik, InDex Pharmaceuticals Holding AB . På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig.

Rights issue in InDex Pharmaceuticals Holding AB SE

' +$select.selected.name }}. {{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}.

The Company is focused in InDex Pharmaceuticals Holding. First North Stockholm. Senast Betalt, Daglig förändring. 1.84 InDex Pharmaceuticals Holding.